• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    iMDx Announces "JPM Week" and "BTIG Snowbird" Conference Participation

    1/7/26 4:05:00 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IMDX alert in real time by email

    NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (NASDAQ:IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan Healthcare Conference.

    LifeSci Advisors 15th Annual Corporate Access Event

    Date: Monday, January 12th

    Location: The Beacon Grand, San Francisco, Calif.

    Format: One-on-one meetings with management

    Additional "JPM Week" Investor Meetings

    Date: Monday, January 12th through Wednesday, January 14th

    Location: San Francisco, Calif.

    Format: One-on-one meetings with management

    BTIG 13th Annual Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

    Date: February 9th – 11th

    Location: Cliff Lodge, Snowbird, Utah

    Format: One-on-one meetings and skiing with management



    To request an in-person meeting with management on Monday, January 12th, during the week of the 44th Annual J.P. Morgan Healthcare Conference, either register at LifeSci Partners Corporate Access Event 2026 or contact our LifeSci Partners representatives Alexandra Grossman (alex@lifesciadvisors.com). For meetings at the BTIG conference, please contact your sales representative at BTIG.

    About Insight Molecular Diagnostics, Inc.

    Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.Insight Molecular Diagnostics.com/ for more information.

    Investor Contact:

    Doug Farrell

    LifeSci Advisors LLC

    dfarrell@lifesciadvisors.com



    Primary Logo

    Get the next $IMDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

    -Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation- NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), and the American Society of Transplant Surgeons (ASTS) today announced the selection of Kenneth Andreoni, MD, Surgical Director of Kidney Transplantation at Thomas Jefferson University, and Kenneth Chavin, MD, MBA, PhD, FACS, of Temple Health, as the recipients of the ASTS-iMDx Research Grant for Understanding the Health Economics of In-House versus Send-Out of donor-derived cell-free DNA (dd-cfDNA) testing. The pursuit of this research is timely as the transpla

    6/22/26 2:07:31 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry

    Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitorGraftAssure's industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the premier, peer-reviewed scientific publication of the Association for Diagnostics & Laboratory Medicine. The article highlights the concordant performance between iMDx's digital-PCR-based flagship

    6/16/26 4:05:00 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

    American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA aloneGraftAssure™ assay doubles reliability of positive results in screening cohortIn for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80% NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced an online published article in the American Journal of Transplantation asserting statistical superiority of the company's flagship GraftAssure transplant rejection monitoring assay. IMDx's newly develope

    6/11/26 4:17:27 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IMDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Broadwood Partners, L.P. bought $2,032,251 worth of shares (570,184 units at $3.56) (SEC Form 4)

    4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

    4/27/26 7:08:17 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Large owner Broadwood Partners, L.P. bought $2,999,999 worth of shares (521,739 units at $5.75) (SEC Form 4)

    4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

    2/12/26 7:49:56 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IMDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Silverman Lou was granted 26,943 shares, increasing direct ownership by 74% to 63,507 units (SEC Form 4)

    4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

    6/15/26 6:22:12 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Last Andrew J. was granted 26,943 shares, increasing direct ownership by 68% to 66,452 units (SEC Form 4)

    4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

    6/15/26 6:22:07 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Arno Andrew was granted 32,331 shares, increasing direct ownership by 24% to 168,885 units (SEC Form 4)

    4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

    6/15/26 6:22:01 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IMDX
    SEC Filings

    View All

    Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)

    6/17/26 4:05:18 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Insight Molecular Diagnostics Inc.

    10-Q - Insight Molecular Diagnostics Inc. (0001642380) (Filer)

    5/13/26 4:15:10 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)

    5/13/26 4:10:20 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IMDX
    Leadership Updates

    Live Leadership Updates

    View All

    iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

    Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs. Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experience spanning clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs. His background includes over fifteen years of field-based collaboration with key opinion leaders across multiple therapeu

    1/6/26 8:00:00 AM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IMDX
    Financials

    Live finance-specific insights

    View All

    iMDx to Release First Quarter 2026 Results on May 13, 2026

    NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on Wednesday, May 13, 2026, then host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q1 2026 Earnings Webinar. An archived replay will be available after the call concludes on iMDX's website within the Investors/Events & Presentations section here. About Insight Molecular Diagnostics Inc.Insight Molec

    5/6/26 4:05:00 PM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay

    Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, ScotlandThree posters to be presented at the 63rd European Renal Association (ERA) Congress, June 3–6, 2026 in Glasgow, ScotlandFavorable real-world evidence poster to be presented at the American Transplant Congress (ATC), June 20–24, 2026 in BostonUnaudited first quarter 2026 cash balance of $29.4 million is in line with year-end and Q4 2025 conference call guidanceCompany to host fireside chat and one-on-one meetings with investors at Needham Virtual Healthcare Conference on Wednesday, April 15th NAS

    4/14/26 8:00:00 AM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

    NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q4 2025 Earnings Webinar. An archived replay will be available after the call concludes on iMDx's website within the Investors/Events & Presentations section here. Attendance at 25th Annual Needham Virtual He

    3/20/26 8:00:00 AM ET
    $IMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care